3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
17
Phase 1
12
Phase 1/2
6
Phase NA
1
Phase EARLY_PHASE1
1
Phase 4
1
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Immunoglobulin Light-chain Amyloidosis
1
Interventions
Cisplatin
726
Carboplatin
609
Paclitaxel
579
Cyclophosphamide
516
Radiotherapy
511
Docetaxel
477
Fluorouracil
454
Gemcitabine
438
Doxorubicin
383
Capecitabine
361
Dexamethasone
328
Oxaliplatin
289
pembrolizumab
283
Leucovorin
283
Bevacizumab
275
Etoposide
272
Vincristine
270
Rituximab
246
Prednisone
223
Pemetrexed
217
Cytarabine
205
Drug Therapy
194
Trastuzumab
176
Irinotecan
174
Methotrexate
171
Lenalidomide
137
Nivolumab
136
Filgrastim
135
Epirubicin
129
Tamoxifen
128
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Interventional
×
Blood Component Removal
×
Clear all
NCT02489500
2018-09-10
VelRand
Boston Medical Center
Phase 3
Terminated
3 enrolled
11 charts